A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Portal hypertension; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms PORTICO
- Sponsors Actelion Pharmaceuticals
- 01 Sep 2017 Planned End Date changed from 15 Mar 2018 to 20 Feb 2018.
- 01 Sep 2017 Planned primary completion date changed from 15 Feb 2018 to 17 Oct 2017.
- 01 Sep 2017 Status changed from recruiting to active, no longer recruiting.